The disposition and metabolic fate of14C-meropenem in man
- 1 January 1993
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 23 (11), 1311-1323
- https://doi.org/10.3109/00498259309059441
Abstract
1. The metabolism and pharmacokinetics of 14C-meropenem were studied in five volunteers who received 0-5 g (40 μCi) of the radiolabelled drug by i.v. infusion. 2. The maximum concentration of drug in plasma was 27 ± 2μg/ml (70 μM) corresponding to 98% of plasma radioactivity at the end of a 30 min infusion. The elimination half-life for meropenem in plasma was 1 h and meropenem remained the major radioactive component up to 6 h, but represented a decreasing proportion of the plasma radioactivity with time. One metabolite (the ring-open lactam) accounted for most of the remaining plasma radioactivity. The maximum concentration of metabolite was 1 ± 0.1 μg/ml and the concentration of total radioactivity decreased to 2% of the peak value by 8 h. 3. Over the 5 days of the study, urinary excretion of radioactivity accounted for 99 ± 0.5% dose, most of which was recovered in the first 8 h. There was negligible excretion in faeces. 4. Structural confirmation of the drug-related components in urine was accomplished by h.p.l.c.-mass spectrometry. Meropenem accounted for 71 ± 2% dose of 14C and the ring-open lactam metabolite for most of the remainder, no other metabolites were detected. 5. Meropenem was the major radioactive component in urine up to 8 h after dosing and is therefore remarkably stable to human renal dehydropeptidase (DHP-1) compared with other carbapenems in clinical use.Keywords
This publication has 11 references indexed in Scilit:
- A study of the penetration of meropenem into bile using endoscopic retrograde cholangiographyJournal of Antimicrobial Chemotherapy, 1992
- 14C-labeling of a novel carbapenem antibiotic SM-7338Journal of Labelled Compounds and Radiopharmaceuticals, 1991
- Effect of meropenem on the intestinal microfloraEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy malesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- In-vitro studies of meropenemJournal of Antimicrobial Chemotherapy, 1989
- The pharmacokinetics of meropenem in volunteersJournal of Antimicrobial Chemotherapy, 1989
- Comparative in-vitro activity of meropenem on clinical isolates from the United KingdomJournal of Antimicrobial Chemotherapy, 1989
- Disposition of radiolabeled imipenem and cilastatin in normal human volunteersAntimicrobial Agents and Chemotherapy, 1984
- Thienamycin: development of imipenem-cilastatinJournal of Antimicrobial Chemotherapy, 1983
- Metabolism of Thienamycin and Related Carbapenem Antibiotics by the Renal Dipeptidase, Dehydropeptidase-IAntimicrobial Agents and Chemotherapy, 1982